作者
Marc Arbyn, Guglielmo Ronco, Ahti Anttila, Chris JLM Meijer, Mario Poljak, Gina Ogilvie, George Koliopoulos, Pontus Naucler, Rengaswamy Sankaranarayanan, Julian Peto
发表日期
2012/11/20
来源
Vaccine
卷号
30
页码范围
F88-F99
出版商
Elsevier
简介
More than ever, clinicians need regularly updated reviews given the continuously increasing amount of new information regarding innovative cervical cancer prevention methods. A summary is given from recent meta-analyses and systematic reviews on 3 possible clinical applications of human papillomavirus (HPV) testing: triage of women with equivocal or low-grade cytologic abnormalities; prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN) lesions, and last not but not least, primary screening for cervical cancer and pre-cancer. Consistent evidence is available indicating that HPV-triage with the Hybrid Capture® 2 assay (Qiagen Gaithersburg, Inc., MD, USA [previously Digene Corp.] (HC2) is more accurate (higher sensitivity, similar specificity) than repeat cytology to triage women with equivocal Pap smear results. Several other tests show at least similar accuracy but …
引用总数
20122013201420152016201720182019202020212022202320243488498102104888311471697633
学术搜索中的文章